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ToxinAbstract Botulinum toxin (Botox) is an exotoxin produced from Clostridium botulinum. It blocks
the release of acetylcholine from the cholinergic nerve end plates resulting in inactivity of the mus-
cles or glands innervated. The efﬁcacy of Botox in facial aesthetics is well established; however,
recent literature has highlighted its utilization in multiple non-cosmetic medical and surgical condi-
tions. The present article reviews the current evidence pertaining to Botox use in the non-cosmetic
head and neck conditions. A literature search was conducted using MEDLINE, EMBASE, ISI Web
of Science and the Cochrane databases limited to English Language articles published from January
1980 to December 2014. The ﬁndings showed that there is level 1 evidence supporting the efﬁcacy of
Botox in the treatment of laryngeal dystonia, headache, cervical dystonia, masticatory myalgia, sial-
orrhoea, temporomandibular joint disorders, bruxism, blepharospasm, hemifacial spasm and rhini-
tis. For chronic neck pain there is level 1 evidence to show that Botox is ineffective. Level 2 evidence
exists for vocal tics and trigeminal. For stuttering, facial nerve paresis, Frey’s syndrome and oro-
mandibular dystonia the evidence is level 4. Thus, there is compelling evidence in the published lit-
erature to demonstrate the beneﬁcial role of Botox in a wide range of non-cosmetic conditions
pertaining to the head and neck (mainly level 1 evidence). With more and more research, the range
of clinical applications and number of individuals getting Botox will doubtlessly increase. Botox
appears to justify its title as ‘the poison that heals’.
 2016 The Author. Production and Hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ce based
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Botulinum toxin (Botox) is a protease exotoxin produced by a
Gram-positive, rod-shaped, anaerobic, spore-forming, motile
bacterium called Clostridium botulinum. When released, it
causes inactivity of muscles or glands by blocking the release
of acetylcholine from cholinergic nerve endings. Although its
effects are short-lived, varying the frequency and dosage of
administration may alter them. Botox is a standout among
the most powerful normally occurring organic toxins and in
the past has been in charge of numerous inadvertent deaths
before its disclosure in prescription. It was ﬁrst used in medi-
cine in 1980 to treat strabismus. Although in 1989, the cos-
metic effects of Botox on wrinkles were noticed, it was only
in 2002, that it gained global recognition as a potential cos-
metic therapeutic agent after the approval from Food and
Drug Administration (Lang, 2004).
As of late, the therapeutic uses of Botox have extended
exponentially to incorporate an extensive variety of medical
and surgical conditions. This has been helped by a more note-
worthy comprehension of its hidden physiology and in addi-
tion enhanced efﬁcacy and safety. This review evaluates the
evidence on Botox use in non-cosmetic conditions of the head
and neck.Please cite this article in press as: Awan, K.H. The therapeutic usage of botulinum
review. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.02. Materials and methods
2.1. Search strategy
Detailed automated literature searches of MEDLINE,
EMBASE, ISI Web of Science and the Cochrane databases
limited to English Language articles published from January
1980 to December 2014 were conducted. The search strategy
was based on the recommendation of Oxford Center for
Evidence-Based Medicine. The following keywords and Boo-
lean operators were used, ‘botox’ and ‘larynx’ or ‘dysphonia’
or ‘dystonia’ or ‘tremor’ or ‘oral’ or ‘myoclonus’ or ‘temporo
mandibular’ or ‘sialorrhoea’ or ‘bruxism’ or ‘oesophagus’ or
‘dysphagia’ or ‘speech’ or ‘face’ or ‘autonomic nervous system’
or ‘sweating’ or ‘torticollis’ or ‘pain’ or ‘migraine’ or ‘head-
ache’ or ‘myalgia’ or ‘neuralgia’ or ‘nose’ or ‘rhinitis’.
2.2. Data collection and extraction
Titles and abstract of the studies that fulﬁlled the criteria were
initially screened. Full texts of the studies that were found rel-
evant judged by the abstract were independently and manually
assessed. Further references were obtained through their
bibliographies.toxin (Botox) in non-cosmetic head and neck conditions – An evidence based
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Table 2 Levels of evidence for the role of Botox in various non-cosmetic head and neck conditions.
Conditions Highest level of
evidence
Laryngeal condition
Laryngeal dystonia (Boutsen et al., 2002; Brazeau, 2010) 1a
Stuttering or stammering (Brin et al., 1994) 4
Vocal tics (Kwak et al., 2000; Marras et al., 2001; Porta et al., 2004) 2b
Pain
Headache (Aurora et al., 2010; Diener et al., 2010; Dodick et al., 2010; Jackson et al., 2012) 1a
Cervical dystonia (Costa et al., 2005a, 2005b) 1a
Masticatory myalgia (Guarda-Nardini et al., 2008; Kurtoglu et al., 2008; von Lindern et al., 2003) 1b
Chronic neck pain (Langevin et al., 2011) 1a
Trigeminal neuralgia (Bohluli et al., 2011; Turk et al., 2005; Zuniga et al., 2008) 2b
Oral conditions
Sialorrhoea (Lagalla et al., 2006; Mancini et al., 2003; Ondo et al., 2004) 1b
Temporomandibular joint disorders (Guarda-Nardini et al., 2008; von Lindern et al., 2003; Denglehem et al., 2012) 1b
Bruxism (Guarda-Nardini et al., 2008) 1b
Oromandibular dystonia (Mendes and Upton, 2009; Moller et al., 2007) 4
Facial conditions
Blepharospasm (Fahn et al., 1985; Frueh et al., 1988; Jankovic, 1988b) 1b
Hemifacial spasm (Yoshimura et al., 1992) 1b
Facial nerve paresis (Naik et al., 2008; Reddy and Woodward, 2010; Toﬀola et al., 2010) 4
Nasal condition
Rhinitis (Yang et al., 2008; Rohrbach et al., 2009; Sapci et al., 2008; Ozcan et al., 2006) 1b
Autonomic conditions
Frey’s syndrome (Beerens and Snow, 2002; Cantarella et al., 2010; de Bree et al., 2009; Drobik and Laskawi, 1995;
Pomprasit and Chintrakarn, 2007; Steﬀen et al., 2012)
4
Table 1 Levels of evidence based on the Oxford Centre for Evidence-Based Medicine.
Level of evidence Type of study
1a Systematic review with homogeneitya of randomized control trials
1b Individual randomized control trial with a narrow conﬁdence interval
1c All or none related outcomeb
2a Systematic review with homogeneity of cohort studies
2c Individual cohort study (including low-quality randomized control trials e.g., <80% follow-up)
3a ‘‘Outcomes” Research; Ecological studies
3b Individual case-control study
4 Case-series (and poor-quality cohort and case-control studiesc)
5 Expert opinion without explicit critical appraisal, or based on physiology, bench research or ‘‘ﬁrst principles”
a Refers to a systematic review that is free of worrisome variations (heterogeneity) in the directions and degree of results between individual
studies.
b Refers to when all patients died before the treatment became available, but some now survive on it, or when some patients died before the
treatment became available, but none now die on it.
c Refers to a cohort study that failed to clearly deﬁne comparison groups and/or failed to measure exposures and outcomes in the same
(preferably blinded), objective way in both exposed and non-exposed individuals and/or failed to identify or appropriately control known
confounders and/or failed to carry out a sufﬁciently long and complete follow-up of patients.
The therapeutic usage of botulinum toxin (Botox) 33. Results
Initial search yielded a total of 997 English language studies.
After review of the titles and abstracts, 88 studies were found
relevant and are presented in this review. Evidence levels,
based on those suggested by the Oxford Centre for Evidence-
Based Medicine (Table 1) (http://www.cebm.net/index.aspx?
o=1025), are shown in the text inside [ ]. The highest level
of evidence pertaining to Botox treatment for each of the
ENT conditions is presented in Table 2.Please cite this article in press as: Awan, K.H. The therapeutic usage of botulinum
review. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.04. Discussion
4.1. Laryngeal conditions
4.1.1. Laryngeal dystonia
Laryngeal dystonia is caused by spasm of intrinsic laryngeal
muscles resulting in unseemly closure or opening of glottis.
Symptoms include hypophonia and breathy voice (abductor
type) or hoarseness and strangled speech breaks (adductor
type) (Rosenﬁeld et al., 1990). A meta-analysis of 30toxin (Botox) in non-cosmetic head and neck conditions – An evidence based
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4 K.H. Awanrandomized controlled trials (RCTs) involving Botox therapy
in adductor laryngeal dystonia demonstrated an improvement
to about one standard deviation across the dependent voice-
related Quality of Life (QoL) variables examined (Boutsen
et al., 2002; Brazeau, 2010). A subsequent RCT likewise
afﬁrmed the beneﬁcial effects of Botox in laryngeal dystonia
and showed greatest improvement among those patients who
were most signiﬁcantly disabled [1b] (Cannito et al., 2004).
Furthermore, a recent prospective study (n= 133) has shown
a mean Voice Handicap Index improvement of 9.6% after
laryngeal Botox administration in patients with laryngeal dys-
tonia (Novakovic et al., 2011).
4.1.2. Stuttering or stammering
Stuttering or stammering is a disorder of selection, initiation,
and execution of motor sequences necessary for ﬂuent speech
production. The disruption in the ﬂow of speech is caused by
poor coordination between lingual, labial, laryngeal and respi-
ratory muscles resulting in involuntary repetitions and prolon-
gation of sounds, syllables, words or phrases, with occasional
involuntary silent pauses. There is only one case series that has
demonstrated an improvement in speech ﬂuency among
patients who were administered with intralaryngeal Botox
injections; therefore, its value in treating this disorder is ﬂawed
and necessitates further research [4] (Brin et al., 1994).
4.1.3. Vocal tics (Gille de la Tourette syndrome)
This refers to sudden, repetitive, nonrhythmic vocalization as a
result of repetitive dyskinetic movement of the laryngeal mus-
culature. This is commonly seen in Gille de la Tourette syn-
drome. It may range from simple vocal tics such as throat
clearing, snifﬁng, or grunting to more complex ones such as
echolalia (repeating words just spoken by someone else), pali-
lalia (repeating one’s own previously spoken words), lexilalia
(repeating words after reading them), and coprolalia (the spon-
taneous utterance of socially objectionable or taboo words or
phrases). Although there is one RCT that demonstrated that
Botox injections into the thyroarytenoid muscles is effectual
in decreasing the recurrence and inclination of vocal and
motor tics (n= 18) [2b], the patients did not report a general
advantage from the treatment (Kwak et al., 2000; Marras
et al., 2001; Porta et al., 2004). Again, further research is
required to assess the efﬁcacy of Botox for vocal tics.
4.2. Pain
4.2.1. Headache
A number of multicenter double-blind placebo-controlled
trials have demonstrated the efﬁcacy of Botox as a prophylac-
tic therapy for migraine [1a] (Aurora et al., 2010; Diener et al.,
2010; Dodick et al., 2010). The procedure includes administra-
tion of Botox injections into muscles innervated by the trigem-
inal or facial nerves or speciﬁc pain distribution sites or a
combination of both (Durham and Cady, 2011). Signiﬁcant
decrease from baseline was observed in patients in the Botox
trial arm with regard to headache and migraine days, total
hours of headache and recurrence of moderate/severe head-
ache days. A recent meta-analysis afﬁrmed these valuable
effects of Botox, but only in the treatment of chronic daily
headaches and chronic migraines (>15 episodes per month)
[1a]. The review also reported adverse effects includingPlease cite this article in press as: Awan, K.H. The therapeutic usage of botulinum
review. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.0blepharoptosis, skin tightness, paraesthesias, neck stiffness,
muscle weakness and neck pain at the injection sites; however,
these were insigniﬁcant and transient (Jackson et al., 2012).
4.2.2. Cervical dystonia or spasmodic torticollis
This refers to an chronic neurological movement disorder
causing the neck to involuntarily turn to the left, right,
upward, and/or downward resulting in signiﬁcant cervical pain
and abnormal cervical postures. It can be primary of sec-
ondary to other neurological disorders (Velickovic et al.,
2001). The evidence supporting the utilization of Botox in
the treatment of cervical dystonia comprises of two Cochrane
systematic reviews of 13 (677 members for Botox An) and
three (308 members for Botox B) high-quality RCTs, respec-
tively [1a] (Costa et al., 2005a, 2005b). These meta-analyses
demonstrated that solitary injection of Botox is effective
(as apparent from both objective and subjective rating scales)
and can be securely rehashed if needed. Since then, there have
been further RCTs afﬁrming the efﬁcacy and safety of Botox
in the treatment of cervical dystonia in both previously treated
and Botox-naive patients [1b] (Comella et al., 2011). Studies
have shown that Botox not only lessens irregular movements
and contractures but also avert secondary degenerative
changes of cervical spine and related radiculopathy (Jankovic
et al., 2011; Ruiz et al., 2011).
4.2.3. Masticatory myalgia
Masticatory pain may be a result of chronic nociceptive irrita-
tion of the tendons and fascias of the masseter, temporalis and
medial pterygoid muscles (Clark, 2008; Solberg, 1986). There
are three RCTs indicating Botox to be more viable than pla-
cebo (saline) in lessening masticatory myalgia [1b] (Guarda-
Nardini et al., 2008; Kurtoglu et al., 2008; von Lindern
et al., 2003). The latest of these three RCTs additionally
assessed the action potential of the masseter and temporalis
muscles with EMG and demonstrated that these diminished
by nearly 80% on day 14, and by 25% on day 28 after Botox
administration (Kurtoglu et al., 2008). Botox causes a disuse
atrophy of the affected muscle, which mitigates strain,
enhances aerobic metabolism and enables decompression of
afferent nociceptive neurons by decreasing substance
P-mediated neurogenic inﬂammation (Bhogal et al., 2006;
von Lindern et al., 2003).
4.2.4. Chronic neck pain
A number of studies have examined the role of intramuscular
Botox injection in chronic neck pain; however, no critical
advantageous impact has been illustrated. A recent Cochrane
systematic review of nine trials (503 participants) demon-
strated that Botox alone was no superior to the placebo
(saline) for patients with subacute or chronic neck pain and
reported that the available evidence does not support the uti-
lization of Botox either as a monotherapy or in combination
with any other treatment in patients suffering from subacute
or chronic neck pain [1a] (Langevin et al., 2011).
4.2.5. Trigeminal neuralgia
The role of Botox in the treatment of drug refractory trigemi-
nal neuralgia has been assessed in three studies (n= 15,
n= 12, and n= 8, respectively) (Bohluli et al., 2011; Turktoxin (Botox) in non-cosmetic head and neck conditions – An evidence based
4.024
The therapeutic usage of botulinum toxin (Botox) 5et al., 2005; Zuniga et al., 2008). All three studies (including a
low-quality RCT) observed Botox to be a viable treatment
with most of the patients reporting a lessening or even vanish-
ing of the pain [2b] (Bohluli et al., 2011; Turk et al., 2005;
Zuniga et al., 2008). Botox was observed to be effective in
combination with pharmacotherapy, prior to considering more
invasive therapies such as surgery or gamma knife radio-
surgery (Bohluli et al., 2011). As such, Botox is an especially
effective treatment modality for elderly patients and those with
adverse anesthetic comorbidities (Allam et al., 2005; Ngeow
and Nair, 2010).
4.3. Oral conditions
4.3.1. Sialorrhoea
Sialorrhoea, deﬁned as an overﬂow of saliva from the mouth
(drooling), negatively affects both patient’s quality of life
and social interactions. It may occur in neurological and other
akinetic disorders, for example, Parkinson’s disease and cere-
bral paralysis. There are a few RCTs where the competence
of Botox injections to the parotid and/or submandibular
glands in such patients has been presented, with effects lasting
3–6 months and no major adverse effects [1b] (Lagalla et al.,
2006; Mancini et al., 2003; Ondo et al., 2004). Likewise, Botox
injections can be utilized in patients with sialorrhoea caused by
salivary ﬁstulas and sialadenitis (Ellies et al., 2004).
4.3.2. Temporomandibular joint disorders
Chronic recurrent temporomandibular joint (TMJ) dislocation
is an uncommon condition that is agonizing and upsetting to
patients and exceptionally trying for the clinicians. Sustained
TMJ dislocation is not manageable by manual reduction alone
when the etiology is muscular in nature. Spasm of lateral
pterygoid muscles may result in anterior displacement of
TMJ with excruciating pain and clicking. Several RCTs pro-
vide supporting evidence for the utilization of Botox in the
management of such TMJ disorders [1b] (Guarda-Nardini
et al., 2008; von Lindern et al., 2003; Denglehem et al.,
2012). However, administration of Botox into the lateral ptery-
goid muscles may bring about a ‘ﬁxed’ smile because of dis-
semination of the toxin into the superﬁcial facial muscles
(Chikhani and Dichamp, 2003).
4.3.3. Bruxism
Bruxism is described as non-functional contact of the
mandibular and maxillary teeth resulting in clenching or tooth
grinding due to repetitive, unconscious contraction of the mas-
seter and temporalis muscles (Behr et al., 2012). There is one
RCT (n= 30) which has demonstrated Botox to be adequate
in lessening myofascial pain symptoms in bruxers compared
to control patients who were administered saline placebo injec-
tions [1b] (Guarda-Nardini et al., 2008). More randomized
controlled studies are needed to conﬁrm that Botox is safe
and reliable for routine clinical use in bruxism.
4.3.4. Oromandibular dystonia
Oromandibular dystonia is a focal dystonia characterized by
involuntary, forceful contractions of the face, jaw, and/or ton-
gue causing difﬁculty in opening and closing the mouth and
often affecting chewing and speech. It is often associated withPlease cite this article in press as: Awan, K.H. The therapeutic usage of botulinum
review. Saudi Pharmaceutical Journal (2016), http://dx.doi.org/10.1016/j.jsps.2016.0dystonia of the neck muscles (cervical dystonia/spasmodic tor-
ticollis), eyelids (blepharospasm), or larynx (spasmodic dys-
phonia). Symptoms include dysphagia, dysarthria, bruxism
and temporomandibular joint subluxation. There are case-
series and case reports [4] showing encouraging results of
Botox administration into the masseter, lateral pterygoid,
and anterior belly of digastric and temporalis muscles
(Mendes and Upton, 2009; Moller et al., 2007). Therefore,
there is a need to carry out high-quality studies to ascertain
the true role of Botox in the management of oromandibular
dystonia.
4.4. Facial conditions
4.4.1. Blepharospasm
It is characterized by abnormal, involuntary, bilateral contrac-
tion or twitching of the eyelids muscles. Symptoms include
Excessive blinking and spasming of the eyes, uncontrollable
contractions or twitches of the eye muscles and surrounding
facial area, dryness of the eyes and sensitivity to the sun and
bright light. The use of Botox for the treatment of ble-
pharospasm was ﬁrst reported in 1985 and has since become
the treatment of choice (Jankovic, 1988a, 1988b; Scott et al.,
1985). There are three RCTs that have demonstrated the pre-
dominance of Botox over placebo [1b] (Fahn et al., 1985;
Frueh et al., 1988; Jankovic, 1988a, 1988b). In a recent
Cochrane systematic review, the authors reported that it would
be unethical to carry out more RCTs to demonstrate the use-
fulness of Botox over the placebo (saline) because of the high
efﬁcacy and evident advantages of Botox in treating ble-
pharospasm (Costa et al., 2005c).
4.4.2. Hemifacial spasm
This is a rare neuromuscular disease characterized by irregular,
recurrent, involuntary muscle contractions on one side of the
face. Although there are multiple theories to explain the facial
nerve dysfunction found in hemifacial spasm, it is generally
accepted that it is caused by compression of the facial nerve
near its origin by an aberrant branch of the posterior inferior
cerebellar artery (Illingworth et al., 1996). The ﬁrst study to
assess Botox in hemifacial spasm was in 1986 (Elston, 1986).
Since then, there have been a few studies, including one
RCT, which demonstrated Botox to be a powerful and safe
treatment (Yoshimura et al., 1992). This RCT included 11
patients and distinctly exhibited the favorable impact of the
Botox over the placebo [1b].
4.4.3. Facial nerve paresis
In acute phase of facial nerve paresis, Botox may be utilized to
induce therapeutic ptosis to protect the cornea. Transcuta-
neous injections of Botox are administered into Mueller’s mus-
cle and the levator palpebrae superioris. There are only two
case-series showing therapeutic chemodenervation of these
muscles with Botox (Naik et al., 2008; Reddy and
Woodward, 2010). Both demonstrated that Botox is not only
useful in preventing damage to the cornea but also facilitates
in the healing process [4]. Furthermore, there is one case-
series of 30 patients demonstrating the efﬁcacy of Botox to
reduce synkinesis in aberrant facial nerve regeneration follow-
ing facial nerve paresis (Toffola et al., 2010). In this case-series,
Botox was injected to a number of synkinetic muscles of all 30toxin (Botox) in non-cosmetic head and neck conditions – An evidence based
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improvement [4].
4.5. Nasal conditions
4.5.1. Rhinitis
A number of RCTs have shown beneﬁcial effects of Botox in
patients with rhinitis. In a RCT of 39 patients with allergic
rhinitis, Botox treatment demonstrated preferable symp-
tomatic control over steroid injections into each inferior turbi-
nate, both in terms of the duration and degree of symptoms
[1b] (Yang et al., 2008). In another RCT of patients with idio-
pathic rhinitis, topical use of Botox showed considerable
reduction in rhinorrhea in comparison with placebo (saline);
however, no change was noted in nasal congestion
(Rohrbach et al., 2009). In a study of 38 patients with idio-
pathic rhinitis, Botox demonstrated comparable results to
ipratropium bromide in controlling hypersecretion symptoms
(Sapci et al., 2008). In a RCT of 30 patients with vasomotor
rhinitis, Botox injections in the middle and inferior turbinate
were demonstrated to be simple, safe and highly effective
[1b] (Ozcan et al., 2006). Although these studies provide
encouraging results for the role of Botox in the treatment of
allergic and idiopathic rhinitis, several limiting factors includ-
ing high cost, specialized training, and potential pain prevent
its widespread use (Nowak and Szyfter, 2011).
4.6. Autonomic conditions
4.6.1. Frey’s syndrome
This is a rare neurological disorder resulting from damage to
or near the parotid glands, and from damage to the auricu-
lotemporal nerve often after surgery. There is aberrant regen-
eration of postganglionic parasympathetic ﬁbers innervating
sympathetic cholinergic sweat glands resulting in sweating,
ﬂushing and piloerection while eating (gustatory sweating)
(Neumann et al., 2011). Several studies have shown the efﬁcacy
of Botox as a treatment modality for Frey’s syndrome [4]
(Beerens and Snow, 2002; Cantarella et al., 2010; de Bree
et al., 2009; Drobik and Laskawi, 1995; Pomprasit and
Chintrakarn, 2007; Steffen et al., 2012). Although Botox is
acclaimed as the safest and most effective treatment for Frey’s
syndrome, higher quality studies involving a more signiﬁcant
number of patients are needed.
5. Conclusion
Botox has certainly been demonstrated to have signiﬁcant
value in the management of a wide range of non-cosmetic con-
ditions pertaining to Otorhinolaryngology and Head & Neck
Surgery. With more and more research, the range of clinical
applications and number of individuals getting Botox will
doubtlessly increase. Botox appears to justify its title as ‘the
poison that heals’.
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